10-Q: Tharimmune Reports Second Quarter 2024 Financial Results and Provides Business Update

Tharimmune, a clinical-stage biotechnology company, released its second quarter 2024 financial results, highlighting progress in clinical trials and strategic pipeline development.

Summary

• Tharimmune reported a net loss of $2.3 million for the three months ended June 30, 2024, and a net loss of $4.6 million for the six months ended June 30, 2024.
• The company's research and development expenses were approximately $1.0 million for the three months ended June 30, 2024, and $2.0 million for the six months ended June 30, 2024.
• General and administrative expenses were $1.4 million for the three months ended June 30, 2024, and $2.7 million for the six months ended June 30, 2024.
• The company had cash and cash equivalents of $7.9 million as of June 30, 2024.
• Tharimmune completed a private placement offering in June 2024, raising approximately $1.8 million in net proceeds.
• The company is developing TH104 for chronic pruritis, TH3215 for HER2/HER3 targets, TH0059 as a bispecific ADC, and TH1940 as a PD-1 Picobody.
• A Phase 1 clinical trial for TH104 showed consistent pharmacokinetic profiles and comparable safety between buccal and intravenous routes of administration.
• The company received positive feedback from the FDA for its Phase 2 clinical trial plan for TH104, confirming a 505(b)(2) approval pathway.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and pipeline development, the company's financial situation and need for additional funding raise concerns. The positive clinical trial results are balanced by the company's financial challenges.

Positives

• The Phase 1 trial results for TH104 are promising, showing good bioavailability and safety.
• Positive FDA feedback on the Phase 2 trial plan for TH104 provides a clear regulatory path.
• The company has a diverse pipeline of therapeutic candidates targeting high-value immuno-oncology targets.
• The recent private placement provides additional funding for operations.
• The company has a strategic focus on novel epitopes of antitumor drug targets.

Negatives

• The company reported a net loss of $4.6 million for the six months ended June 30, 2024.
• The company has recurring negative cash flows from operations.
• The company has an accumulated deficit of approximately $29.3 million as of June 30, 2024.
• The company will need substantial additional funding to support future operating activities.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and the need for additional funding.
• There is no assurance that the company will be able to obtain additional capital on acceptable terms or at all.
• The company's product candidates are subject to the risks and uncertainties inherent in clinical trials and regulatory approvals.
• The company is dependent on third-party suppliers and manufacturers.
• There is no guarantee that the company's products will be accepted in the marketplace.

Future Outlook

The company plans to initiate a Phase 2 trial for TH104 in the latter part of 2024 and advance TH3215, TH0059, and TH1940 into IND-enabling studies in 2025. The company will need substantial additional funding to support future operating activities.

Management Comments

• The company is focused on developing therapeutic candidates in immunology and inflammation with high unmet need.
• The company is advancing TH3215, a bispecific against both HER2 and HER3 antibody, into IND-enabling studies in 2025.
• The company anticipates that TH0059, a HER2/HER3 bispecific ADC, and TH1940, a PD-1 Picobody, will progress to enter IND-enabling studies in 2025.

Industry Context

The company's focus on novel epitopes of antitumor drug targets and the development of bispecific antibodies and ADCs aligns with current trends in immuno-oncology. The development of TH104 for chronic pruritis in PBC addresses a significant unmet need in a rare disease.

Comparison to Industry Standards

• The reported bioavailability of 45.9% for TH104 is within the range of published findings for similar oral and intravenous formulations, suggesting potential for once-daily dosing.
• The safety and tolerability profile of TH104 in the Phase 1 trial is comparable to the FDA-approved intravenous nalmefene, which is a positive indicator for further development.
• The company's approach to developing bispecific antibodies and ADCs is consistent with industry trends in targeted cancer therapies, with companies like Amgen, Regeneron, and Roche also heavily invested in these areas.
• The focus on Picobodies for PD-1 is a novel approach, with potential advantages over full-sized antibodies, but it is still early in development compared to established PD-1 inhibitors from companies like Merck and Bristol-Myers Squibb.
• The company's financial position, with recurring losses and the need for additional funding, is not uncommon for clinical-stage biotech companies, but it highlights the inherent risks and challenges in this sector. Companies like Adaptimmune and Celldex have faced similar challenges in their development journeys.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises.
• Employees may be impacted by the company's financial situation and potential restructuring.
• Patients with chronic pruritis and other conditions may benefit from the company's therapeutic candidates if they are successfully developed and approved.
• Suppliers and creditors may be impacted by the company's financial stability.

Next Steps

• Initiate a Phase 2 trial for TH104 in moderate-to-severe chronic pruritus in PBC patients in the latter part of 2024.
• Advance TH3215, TH0059, and TH1940 into IND-enabling studies in 2025.
• Continue to pursue strategic collaboration opportunities to maximize the value of the pipeline.

Key Dates

Keywords

Tharimmune, biotechnology, clinical trials, TH104, pruritis, PBC, HER2, HER3, PD-1, immuno-oncology, bispecific antibodies, antibody drug conjugates, Picobodies, IND, FDA, financial results, capital raise